Eledon Reports Positive Results From Phase 2A Trial Of Tegoprubart In Patients With Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc., A Patient-Focused Clinical Stage Biopharmaceutical Company, Announced Topline Results From A Phase 2A Clinical Trial Of Tegoprubart (Formerly At-1501) In Patients With Amyotrophic Lateral Sclerosis (Als).Tegoprubart Is An Investigational Humanized Monoclonal Antibody That Inhibits Cd40 Ligand (Cd40L), A Membrane Protein Linked To Increased Peripheral Immune Responses And Neuroinflammation In Als. The 12-Week Trial Included 54 Patients With Als At 13 Treatment Sites In The United States And Canada. The Primary Objectives Of The Study Were To Assess The Safety And Tolerability Of Multiple Doses Of Tegoprubart In Four Sequential, Ascending Dose Cohorts (1, 2, 4, And 8 Mg/Kg). Secondary Outcome Measures Included Pharmacokinetic Assessment Of Multiple Intravenous Doses Of Tegoprubart On Target Engagement And On Pro-Inflammatory Biomarkers Associated With Als. Each Subject Served As Their Own Control, With Changes Being Compared To Baseline.Tegoprubart Successfully Met The Primary Endpoints Of Safety And Tolerability. Adverse Events Were Equally Distributed Across Dose Levels. Tegoprubart Was Well-Tolerated, And No Drug-Related Serious Adverse Events Were Observed. Anti-Drug Antibodies (Adas) Were Present In Less Than 5 Percent Of Samples. All Adas Were Of Low Titer And Did Not Impact Tegoprubart Drug Levels.Tegoprubart Target Engagement Was Demonstrated At The 4 And 8 Mg / Kg Dosing Levels Using Cd40L And Cxcl13 Biomarkers Related To T Cell And B Cell Function, Respectively. A Pro-Inflammatory Als Signature Was Identified, Consisting Of 32 Different Inflammatory Biomarkers In The Tested Population, Including Tnf-A, Mcp1, En-Rage, C-Reactive Protein (Crp), And Il-6. Il-1 Was Not Significantly Detected In The Study Patient Population. Dose Dependent, Significant Reductions Were Observed In Up To 23 Of These Biomarkers, Including Tnf-A, Mcp1, En-Rage, And Crp. Other Pro-Inflammatory Biomarkers Significantly Reduced Included Biomarkers Also Associated With Iga Nephropathy And Kidney Transplant Rejection, Such As Iga, Ige, Igm, C3, Cxcl9, And Cxcl10. While The Study Was Neither Primarily Designed Nor Powered To Assess The Effect Of Tegoprubart On Als Functional Rating Scale (

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!